This is a retrospective study aiming to explore the efficacy and safety of Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab in patients with HER2-positive metastatic breast cancer.
Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab